Overview

* Corcept Q2 2025 revenue grows to $194.4 mln, missing analyst expectations, as per LSEG data

* Net income for Q2 2025 slightly declines to $35.1 mln

* The pharma company repurchased $115.4 mln of common stock in Q2 2025

Outlook

* Corcept guides 2025 revenue at $850 mln to $900 mln

* Company expects improved vendor performance to boost future quarters

Result Drivers

* HYPERCORTISOLISM DEMAND - Increased recognition of hypercortisolism's prevalence led to more screenings and diagnoses, driving demand

* VENDOR CAPACITY - Demand for hypercortisolism treatment outpaced specialty pharmacy vendor's capacity

* EXPENSES RISE - Operating expenses increased significantly, impacting net income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $194.43 $199.40

Revenue mln mln (4

Analysts

)

Q2 EPS $0.29

Q2 Net $35.15

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Corcept Therapeutics Inc ( CORT ) is $138.50, about 49.5% above its July 30 closing price of $69.91

* The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 49 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)